Education
1990
BS | Fudan University
Biophysics and Physiology
2001
PhD | National University of Singapore (rank Top in Asia), IMCB, A-STAR
Molecular and Cell Biology
2004
Post-doc Training (2002-2004) | Yale University
Chemical Genetics Chemical Genomics (advisor: Craig M Crews, AAAS Fellow, Director Yale Center for Molecular Discovery, Lab of Invention of PROTAC technology and FDA-approved drug Carfilzomib/KyprolisTM), Yale University
2007
Promoted to Associate Research Scientist (2004 -2007) after Post-Doc Training | Yale University
Chemical Genetics Chemical Genomics (advisor: Craig M Crews, AAAS Fellow, Director Yale Center for Molecular Discovery, Lab of Invention of PROTAC technology and FDA-approved drug Carfilzomib/KyprolisTM), Yale University
2012
MS, | Simon Business School, University of Rochester, New York
Master Medical Management
2014
MBA, | Simon Business School, University of Rochester, New York
Graduate Business Administration
Post-doctoral Training & Residency
2004 - 2007
Research Faculty, Chemical Biology Drug Mode-of-Action Study,
Chemical Genetics and Chemical Genomics,
Department of MCDB and Yale Center for Molecular Discovery,
Yale University
2002 - 2004
Postdoctoral Fellow, Chemical Genetics and Chemical Genomics, (advisor: Craig M Crews, AAAS Fellow, Director Yale Center for Molecular Discovery, Lab of Invention PROTAC technology and FDA-approved drug Carfilzomib/KyprolisTM), Yale University